Doctors at Geneva University Hospitals will use the company's newly launched SmileMS spectral library search software for LC-MS data to quickly identify toxic compounds in patient samples in the emergency room setting.
Thermo Fisher's sample handling and mass spectrometers will be integrated with IBI's proprietary immunoenrichment technology, and the two firms will develop assays and workflows for the detecting and quantifying low abundance proteins.
Simultaneous qual-quan workflows generate significantly more data than many conventional mass spec assays, posing a challenge for vendors of ensuring that their software offerings keep pace with the expanded capabilities of their hardware.
"It's taking two workflows and allowing you to do it on one workflow, even in some senses in an a priori manner," a company official said, adding the platform is "the most important launch" in the 26 years he's been with the firm.
ISB researchers will use the company's synthetic peptides and HeavyPeptide AQUA standards in their efforts to develop selected-reaction monitoring and multiple-reaction monitoring mass spectrometry assays for each of the roughly 25,000 human proteins.
The company made the disclosures as part of Agilent's fiscal second-quarter earnings report, which showed that total revenues grew 16 percent and that a net loss in the prior-year period swung to a profit in the current quarter.
The researchers developed a hybrid instrument combining elements of a flow cytometer and atomic mass spectrometer, which allows for the quantification of biomarkers in parallel in numbers not achievable with other technologies. They also are aiming to develop a multiplex bead array instrument based on the technology.
The collaboration, which aims to characterize the tryptic peptides of the 5,000 proteins in order to generate mass spectroscopy assays for them, brings together ISB's mass spectroscopy expertise and OriGene's extensive human protein collection.